Company Description
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases.
The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.
It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024.
Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James Sapirstein |
Contact Details
Address: 777 Yamato Road, Suite 502 Boca Raton, Florida 33431 United States | |
| Phone | 561 589 7020 |
| Website | enterothera.com |
Stock Details
| Ticker Symbol | ENTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604191 |
| ISIN Number | US33749P4081 |
| Employer ID | 46-4993860 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James R. Sapirstein M.B.A., R.Ph. | Chief Executive Officer and Chairman |
| Sarah Romano CPA | Chief Financial Officer |
| Amy Chandler-Skerkis | Vice President of Regulatory Affairs, QA and Compliance |
| Martin Krusin M.B.A. | Senior Vice President of Corporate Development |
| Jennifer A. Sealey-Voyksner Ph.D. | Senior Vice President for Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 10-Q | Quarterly Report |
| Sep 11, 2024 | 8-K | Current Report |
| Sep 10, 2024 | 8-K | Current Report |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 29, 2024 | 8-K | Current Report |
| Aug 23, 2024 | 8-K | Current Report |
| Aug 22, 2024 | 8-K | Current Report |
| Aug 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |